1. Home
  2. LGCY vs BRNS Comparison

LGCY vs BRNS Comparison

Compare LGCY & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LGCY
  • BRNS
  • Stock Information
  • Founded
  • LGCY 2009
  • BRNS 2016
  • Country
  • LGCY United States
  • BRNS United Kingdom
  • Employees
  • LGCY N/A
  • BRNS N/A
  • Industry
  • LGCY
  • BRNS Biotechnology: Pharmaceutical Preparations
  • Sector
  • LGCY
  • BRNS Health Care
  • Exchange
  • LGCY NYSE
  • BRNS Nasdaq
  • Market Cap
  • LGCY 87.3M
  • BRNS 28.2M
  • IPO Year
  • LGCY 2024
  • BRNS 2021
  • Fundamental
  • Price
  • LGCY $6.60
  • BRNS $0.82
  • Analyst Decision
  • LGCY Strong Buy
  • BRNS Strong Buy
  • Analyst Count
  • LGCY 2
  • BRNS 2
  • Target Price
  • LGCY $10.65
  • BRNS $3.00
  • AVG Volume (30 Days)
  • LGCY 32.5K
  • BRNS 25.9K
  • Earning Date
  • LGCY 02-13-2025
  • BRNS 05-12-2025
  • Dividend Yield
  • LGCY N/A
  • BRNS N/A
  • EPS Growth
  • LGCY 44.62
  • BRNS N/A
  • EPS
  • LGCY 0.58
  • BRNS N/A
  • Revenue
  • LGCY $52,722,310.00
  • BRNS $14,969,000.00
  • Revenue This Year
  • LGCY $33.77
  • BRNS N/A
  • Revenue Next Year
  • LGCY $19.89
  • BRNS N/A
  • P/E Ratio
  • LGCY $11.38
  • BRNS N/A
  • Revenue Growth
  • LGCY 32.68
  • BRNS 1766.46
  • 52 Week Low
  • LGCY $3.60
  • BRNS $0.64
  • 52 Week High
  • LGCY $10.37
  • BRNS $2.60
  • Technical
  • Relative Strength Index (RSI)
  • LGCY N/A
  • BRNS 51.00
  • Support Level
  • LGCY N/A
  • BRNS $0.68
  • Resistance Level
  • LGCY N/A
  • BRNS $0.97
  • Average True Range (ATR)
  • LGCY 0.00
  • BRNS 0.08
  • MACD
  • LGCY 0.00
  • BRNS 0.02
  • Stochastic Oscillator
  • LGCY 0.00
  • BRNS 54.79

About LGCY LEGACY EDUCATION INC

Legacy Education Inc is engaged in career-focused, post-secondary education services to students at all stages of adult life, from recent high school graduates to working parents.

About BRNS Barinthus Biotherapeutics plc

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.

Share on Social Networks: